RxDoctor Payments Data

Gary Siegel

Virginia Beach, VANPI 1952398778

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $18,500 of the $23,986 with a category attached, or 77.1%. Amgen accounts for 66.7% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $21,133 and has fallen 99.3% since, to $145 in 2023.

$23,986in general payments, 2019–2025

Across 206 payments — averaging $116.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$16K
  • Pfizer$5K
  • AbbVie$695
  • GSK$538
  • Novartis$315
  • Genentech USA, Inc.$251
  • plus $1K from 17 others

What the payments were for

  • Speaking & faculty fees$18,50077%
  • Travel & lodging$5082%
  • Food & beverage$4,95821%
  • Education$200%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →